Skip to main content
Future Journal of Pharmaceutical Sciences

Table 4 The drug-likeness of the newly designed EGFRWT inhibitors

From: Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach

Entry

MW

TPSA

WLOGP

No. of H-bond donors

No of H-bond acceptors

RO5 violations

Synthetic accessibility

SFD1

528.99

86.76

4.16

2

6

1

4.42

SFD2

512.53

86.76

4.07

2

7

1

4.39

SFD3

561

86.76

4.81

2

7

1

4.78

SFD4

544.55

86.76

4.96

2

8

1

4.52

SFD5

536.58

103.83

3.71

2

7

1

4.54

SFD6

512.53

86.76

4.07

2

7

1

4.4

SFD7

544.55

86.76

4.96

2

8

1

4.56

SFD8

530.52

86.76

4.63

2

8

1

4.41

SFD9

546.98

86.76

4.72

2

7

1

4.43

SFD10

530.52

86.76

4.63

2

8

1

4.44

  1. MW molecular weight, TPSA total polar surface area, H-bond hydrogen bond, RO5 rule of five
Back to article page